Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 5:585-589, 1994
© 1994 European Society for Medical Oncology

research-article

Cisplatin-induced delayed emesis: Pattern and prognostic factors during three subsequent cycles

Italian Group for Antiemetic Research*

Correspondence to: Fausto Roila, M.D., Medical Oncology Division, Policlinico Hospital, 06100 Perugia, Italy

BACKGROUND:: Cisplatin-induced delayed emesis has been studied much less than has acute emesis. In particular, its pattern of presentation and prognostic factors have not been evaluated in a large enough patient population submitted to multiple cycles of chemotherapy.

PATIENTS AND METHODS:: Delayed nausea and vomiting occurring in patients submitted to cisplatin (≥50 mg/m2) chemotherapy were analyzed for three consecutive cycles. All patients were treated with the same antiemetic therapy (i.m. dexamethasone and oral metoclopramide) for delayed emesis, while they had received either i.v. ondansetron plus dexamethasone or metoclopramide plus dexamethasone plus diphenhydramine for acute emesis.

RESULTS:: Two hundred forty-nine patients were evaluable at first cycle of chemotherapy, 195 at second and 163 at third. About 25%–30% of patients presented delayed vomit-ing, 40%–45% nausea and 45%–50% nausea and/or vomiting. The percentage of patients suffering from delayed emesis remained similar in the three cycles of chemotherapy. Dose of cisplatin, control of acute emesis and dependence effect from the results obtained in the control of acute and delayed emesis of the previous cycle were found to be the most important prognostic factors of delayed emesis. Adverse events were infrequent and mild. Hiccup was significantly more frequent in patients receiving high-dose metoclopramide.

CONCLUSIONS:: Despite the use of the most efficacious antiemetic treatment, delayed emesis remains an unsolved problem in cisplatin-treated patients. Efforts should be directed to obtain better control of acute and delayed emesis, since they have a mutual influence.

delayed emesis, ondansetron, dexamethasone, metoclopramide


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
M. T Holdsworth and T. Vo-Nguyen
Employment of Substandard Antiemetic Prophylaxis in Recent Trials of Chemotherapy-Induced Nausea and Vomiting
Ann. Pharmacother., November 1, 2005; 39(11): 1903 - 1910.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.